Exacerbations in COPD patients treated with Inhaled Corticosteroids/Long-acting β2 agonists combinations, switching to another combination drugs or inhaler device: A “real – world” study
This study investigates the effects of switching to different devices of the same active substance or between different active substances, in patients with Chronic Obstructive Pulmonary Disease (COPD) treated with Inhaled Corticosteroids (ICS) plus Long-acting β2-adrenergic agonists (LABAs) in terms...
Main Authors: | Diego Sangiorgi, Valentina Perrone, Stefano Buda, Luca Degli Esposti |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-01-01
|
Series: | Cogent Medicine |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2331205X.2017.1304873 |
Similar Items
-
Estimating Inhaled Corticosteroid Exposure from Short-Acting β2-Agonist–Inhaled Corticosteroid Rescue
by: Lugogo N, et al.
Published: (2023-05-01) -
Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting
by: Perrone V, et al.
Published: (2016-11-01) -
Lack of Association between Inhaled Corticosteroid Use and the Risk of Future Exacerbation in Patients with GOLD Group A Chronic Obstructive Pulmonary Disease
by: Sun Hye Shin, et al.
Published: (2022-05-01) -
Adjuvant Inhaled Corticosteroids in Community-Acquired Pneumonia: A Review Article
by: Faeq R. Kukhon, et al.
Published: (2021-05-01) -
Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain
by: Miravitlles M, et al.
Published: (2022-01-01)